New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:22 EDTLBIO, ARGS, AVXT, GALE, GNBTMaidstone Life Sciences to hold a conference
4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference is being held in New York on March 27.
News For LBIO;ARGS;AVXT;GALE;GNBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
18:21 EDTGALEOn The Fly: After Hours Movers
Subscribe for More Information
17:59 EDTGALEGalena announces release of special committee report regarding stock promotion
Galena Biopharma announced the release of a report prepared by the former Special Committee of Galena's board regarding the company's 2012-2014 market visibility campaigns and the sale of shares by insiders in Q1. Some of the findings from the report include: "We found no evidence that, with the exception of Mark Ahn, insiders had knowledge of Dream Team Group's activities before trading in the company 's stock; We found no evidence that officers and directors had material nonpublic information before trading in the company's stock; We found no evidence that the trades by officers and directors in 1Q14 violated company policy; During our investigation, we discovered that another of the company's investor relations firms, Lidingo Holdings, might have engaged in improper conduct relative to the payment of bloggers for promotional articles written about the company; We found that Mark Ahn granted stock options to Lidingo as part of its compensation for its services without Board approval, which is contrary to company policy; Based on these findings of fact, we conclude that it is possible that Lidingo violated Section 17b of the Securities Act of 1933." Shares of Galena are up 6% after hours following the release of the special committee report. Reference Link
September 22, 2014
09:31 EDTGNBTGenerex Biotech announces collaboration with UHN
Subscribe for More Information
07:21 EDTARGSEBD Group to hold a conference
Subscribe for More Information
September 18, 2014
09:09 EDTARGSArgos Therapeutics Phase III ADAPT trial of AGS-003 enrollment surpasses 50%
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use